Pharmacogenomics Testing (PGX)

Pharmacogenomics Testing (PGX)

Pharmacogenomics is the study of genetic variations that influence an individual's response to drugs.  Each person responds uniquely to treatment so the same approach may not be effective or may cause adverse drug effects in other patients.  The implementation of PGX testing helps physicians make informed treatment decisions.  This will lead to better outcomes by decreasing adverse drug events and by increasing the effectiveness of drugs.  Consider the following:

  • 95% of people have at least 1 gene variation that will affect how well drugs will work with their body.
  • Patients have differences in DNA that impact drug metabolism which may increase their likelihood of an adverse drug reaction:
  • More than 85% of the population have detectable variations in their DNA that increase their risk for adverse drug reactions.  
  • Adverse drug reactions are the 4th leading cause of death nationwide with more than 8.6 million cases reported annually. The FDA highlights pharmacogenomics data for more than 130 prescription medications indicating their strong support for testing.